Awaiting an FDA review, Geron Corp. (Nasdaq: GERN) delayed a trial of an embryonic stem cell treatment for spinal cord injury sending the stock price tumbling 75 cents to $6.48.
Geron Delays Stem Cell Trial
August 18, 2009 at 13:18 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.